Vivanta Industries has submitted its audited financial results for the quarter and year ended March 31, 2026, confirming compliance with regulatory disclosure requirements. The statutory auditors, M/S. GMCA & CO, Chartered Accountants, Ahmedabad, have issued an audit report with an unmodified opinion on the company's financial performance for the period.

The declaration was made in compliance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates the submission of audited results to the stock exchanges to ensure transparency and adherence to disclosure norms.

The audit report covers the financial statements for the full fiscal year ending March 31, 2026. An unmodified opinion indicates that the auditors found the financial statements to be free of material misstatements and prepared in accordance with the applicable accounting standards.

Key Details of the Filing

The filing was submitted to BSE Limited on July 1, 2026, by H. A. Parikh, Managing Director of Vivanta Industries. The submission ensures that the audited financial results are available on the public record for shareholders and regulatory bodies.

vivanta industries has executed business collaboration agreements with Qness Pharmaceuticals to strengthen its operations in the pharmaceutical sector. The agreements, signed on June 12, 2026, focus on the manufacture, procurement, supply, branding, marketing, and distribution of pharmaceutical and allied products within the domestic market. This strategic move aims to expand the company's product portfolio and enhance its market reach through contract manufacturing and supply arrangements.

The collaboration does not involve any joint venture, equity participation, or share exchange. No upfront consideration has been paid or received as part of the arrangement. Instead, commercial considerations will be determined based on individual purchase orders and mutually agreed commercial terms from time to time. The agreements provide a framework for operations while ensuring that ownership of intellectual property remains with the respective owner.

Qness Pharmaceuticals is a proprietorship concern engaged in the business of pharmaceutical products. The counterparty is not a related party of Vivanta Industries Limited. The Promoters, Promoter Group, and Group Companies of Vivanta Industries Limited have no interest in the said arrangements, and all transactions are proposed to be undertaken on an arm's length basis.

The agreements do not result in any transfer of management or control of Vivanta Industries Limited. Product-wise pricing and operational terms shall be governed through mutually agreed purchase orders. The company expects these arrangements to create opportunities for business growth by leveraging contract manufacturing capabilities.

In the event that the arrangements are terminated or called off for any reason, Vivanta Industries Limited will make appropriate disclosures to the Stock Exchange along with the reasons thereof. This will be done in accordance with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Details of the Agreement